PET/CT in Non-Hodgkin Lymphoma: An Update

被引：39

作者：

Zanoni, Lucia ^{[1
]}

Bezzi, Davide ^{[2
]}

Nanni, Cristina ^{[1
]}

Paccagnella, Andrea ^{[2
,3
]}

Farina, Arianna ^{[2
]}

Broccoli, Alessandro ^{[4
,5
]}

Casadei, Beatrice ^{[4
,5
]}

Zinzani, Pier Luigi ^{[4
,5
]}

Fanti, Stefano ^{[1
,2
]}

机构：

[1] Univ Bologna, Nucl Med, IRCCS Azienda Ospedaliero, Via Massarenti 9, I-40138 Bologna, Italy

[2] Alma Mater Studiorum Univ Bologna, Nucl Med, Bologna, Italy

[3] AUSL Romagna, Nucl Med Unit, Cesena, Italy

[4] Univ Bologna, Ist Ematol Seragnoli, IRCCS Azienda Ospedaliero, Bologna, Italy

[5] Univ Bologna, Dipartimento Med Specialist Diagnost & Sperimenta, Bologna, Italy

来源：

SEMINARS IN NUCLEAR MEDICINE | 2023年 / 53卷 / 03期

关键词：

B-CELL LYMPHOMA; POSITRON-EMISSION-TOMOGRAPHY; METABOLIC TUMOR VOLUME; INTERIM FDG-PET/CT; END-OF-TREATMENT; BURDEN FOLLICULAR LYMPHOMA; MINIMAL RESIDUAL DISEASE; BONE-MARROW INVOLVEMENT; CORE-NEEDLE-BIOPSY; T-CELL;

D O I：

10.1053/j.semnuclmed.2022.11.001

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative disorders characterized by different clinical courses, varying from indolent to highly aggressive. 18F-FDG-PET/CT is the current state-of-the-art diagnostic imaging, for the staging, restaging and evaluation of response to treatment in lymphomas with avidity for 18F-FDG, despite it is not routinely recommended for surveillance. PET-based response criteria (using fivepoint Deauville Score) are nowadays uniformly applied in FDG-avid lymphomas. In this is provided, at each relevant point of patient management, particularly focusing on recent advances on diffuse large B-cell lymphoma and follicular lymphoma, with brief updates also on other histotypes (such as marginal zone, mantle cell, primary mediastinal- B cell lymphoma and T cell lymphoma). PET-derived semiquantitative factors useful for patient stratification and prognostication and emerging radiomics research are also presented. Semin Nucl Med 53:320-351 (c) 2022 Published by Elsevier Inc.

引用

页码：320 / 351

页数：32

共 270 条

[1] Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].